NHWA(SZ:002262) Zheng Quan Zhi Xing·2025-08-11 16:16Core Viewpoint - Jiangsu Enhua Pharmaceutical Co., Ltd. has announced the first unlock period for its 2024 restricted stock incentive plan, allowing 750 participants to unlock a total of 2,264,451 shares, which represents 0.2229% of the company's total share capital of 1,015,786,583 shares [1][5][12]. Summary by Sections Incentive Plan Approval - The company held meetings on July 29, 2025, where the board and supervisory committee approved the conditions for unlocking the restricted stocks under the 2024 incentive plan [1][2]. - The incentive plan was publicly disclosed, and no objections were raised during the public notice period [2]. Stock Unlocking Details - The first unlock period allows for 30% of the granted restricted stocks to be unlocked, contingent upon meeting specific performance criteria [5][10]. - The performance target for 2024 requires a net profit growth of at least 15% compared to 2023, with the audited net profit for 2024 set at approximately 1.17 billion yuan, achieving a growth rate of 15.48% [7][10]. Performance Assessment - The personal performance assessment for the incentive participants requires a score of at least 80% to qualify for unlocking [8][10]. - A total of 750 participants met the performance criteria, while 54 participants did not qualify for unlocking due to performance issues [10][12]. Changes in Share Capital Structure - Following the unlocking, the company's share capital structure will reflect a decrease in restricted shares from 13.21% to 12.98% of total shares, while unrestricted shares will increase from 86.79% to 87.02% [12][13]. - The total number of restricted shares post-unlocking will be 5,934,040 shares [12].